News Releases | Investor Relations - Sangamo Therapeutics, Inc.
Nov 12, 2024 · - Agreement grants Astellas rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - Sangamo to receive a $20 million upfront license fee and is eligible to earn up to …
Sangamo Therapeutics to Regain Full Rights to Hemophilia A …
Dec 30, 2024 · - Based on positive results from Phase 3 AFFINE trial, which met primary and secondary endpoints, Sangamo plans to explore all options to commercialize the asset, including seeking a potential new collaboration partner
Sangamo Therapeutics and Astellas Announce Capsid License …
Dec 19, 2024 · - Agreement grants Astellas rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - Sangamo to receive a $20 million upfront license fee and is eligible to earn up to $1.3 billion in additional licensed target fees and milestone payments across all five potential disease targets ...
Sangamo Therapeutics Announces U.S. FDA Clearance of IND …
Nov 19, 2024 · Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including the central nervous system.
Sangamo Therapeutics Reports Recent Business Highlights and …
Feb 22, 2023 · BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 22, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2022 financial results.
Sangamo Therapeutics Reports Recent Business Highlights and …
Aug 4, 2022 · Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing ...
Investors & Media - Sangamo Therapeutics, Inc.
Dec 12, 2021 · Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don’t exist.
Sangamo Therapeutics Announces Completion of Public Offering …
RICHMOND, Calif., April 8, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the completion of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a price to the public of $11.50 per share, including 1,650,000 shares sold pursuant to the exercise in full of the ...
Mogrify and Sangamo announce collaboration and exclusive …
Apr 21, 2020 · “This license agreement provides Sangamo with access to Mogrify’s cell conversion technology, which will diversify our options as we develop off-the-shelf allogeneic CAR-Treg cell therapies,” said Jason Fontenot, SVP, Head of Cell Therapy at Sangamo. “We expect this collaboration to accelerate our development of scalable and accessible ...
Sangamo Therapeutics Announces Third Quarter 2023 Conference …
Oct 25, 2023 · BRISBANE, Calif.--(BUSINESS WIRE)--Oct. 25, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2023 financial results after the market closes on Wednesday, November 1, 2023.
- Some results have been removed